Pyrrolidine derivatives
    3.
    发明授权
    Pyrrolidine derivatives 有权
    吡咯烷衍生物

    公开(公告)号:US08618303B2

    公开(公告)日:2013-12-31

    申请号:US13342122

    申请日:2012-01-02

    IPC分类号: C07D401/06 A61K31/445

    摘要: The invention provides compounds of formula wherein R1, R2, R3, R4, R5, and R6 are as defined herein or a pharmaceutically suitable acid addition salt thereof. The present compounds are high potential NK-3 receptor antagonists useful for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

    摘要翻译: 本发明提供下式的化合物,其中R 1,R 2,R 3,R 4,R 5和R 6如本文所定义,或其药学上合适的酸加成盐。 本发明化合物是可用于治疗抑郁症,疼痛,精神病,帕金森病,精神分裂症,焦虑和注意缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。

    Piperidine derivatives as NK3 receptor antagonists
    4.
    发明授权
    Piperidine derivatives as NK3 receptor antagonists 有权
    哌啶衍生物作为NK3受体拮抗剂

    公开(公告)号:US08324248B2

    公开(公告)日:2012-12-04

    申请号:US12692680

    申请日:2010-01-25

    IPC分类号: A61K31/445 C07D401/14

    摘要: The present invention relates to a compounds of formula I wherein A, Ar1, Ar2, R1, R2, R3, R4, R5, R6, m, n, o, p, s, t, and u are as defined herein or to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

    摘要翻译: 本发明涉及式I化合物,其中A,Ar1,Ar2,R1,R2,R3,R4,R5,R6,m,n,o,p,s,t和u如本文所定义, 药物活性盐,外消旋混合物,对映体,旋光异构体或其互变异构形式。 本发明化合物是用于治疗抑郁症,疼痛,精神病,帕金森病,精神分裂症,焦虑和注意缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。

    PIPERAZINE THIAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF TAUOPATHIES SUCH AS ALZHEIMER'S DISEASE
    9.
    发明申请
    PIPERAZINE THIAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF TAUOPATHIES SUCH AS ALZHEIMER'S DISEASE 有权
    用于治疗诸如阿尔茨海默病的TAUOPATHIES的哌嗪衍生物

    公开(公告)号:US20140206699A1

    公开(公告)日:2014-07-24

    申请号:US14238905

    申请日:2012-08-17

    摘要: The present invention relates to a compound of formula (IA), wherein G1 is lower alkyl; lower alkyl substituted by one or more halogens; cycloalkyl; tetrahydropyran-4-yl; phenethyl; phenethyl substituted by one or more halogens; phenoxymethyl; phenoxymethyl substituted by one or more halogens; benzyloxyethyl; benzyloxy-ethyl substituted by one or more halogens; or is —NR2R3; R2 is hydrogen or lower alkyl; R3 is lower alkyl; tetrahydropyran-4-yl; —CH2-cycloalkyl; or cycloalkyl optionally substituted by lower alkyl substituted by one or more halogens; or R2 and R3 form together with the N-atom to which they are attached a heterocycloalkyl group with 4 or 5 carbon atoms, which is optionally substituted by one or more substituents selected from halogen; or lower alkyl substituted by one or more halogens; X is —CH2— or —(CH2)2—; Ar is phenyl or pyridinyl; R4 is halogen; lower alkyl; lower alkyl substituted by one or more halogens; or lower alkoxy; n is 1 or 2; or to a pharmaceutically active salt thereof, to a stereoisomeric form, including an individual diastereoisomer or enantiomer of the compound of formula (IA) as well as to a racemic or non-racemic mixture thereof. The present invention also relates to the use of a compound of formula (IA) for treating certain neurodegenerative disorders characterized by cytotoxic TAU misfolding and/or aggregation.

    摘要翻译: 本发明涉及式(IA)化合物,其中G 1为低级烷基; 被一个或多个卤素取代的低级烷基; 环烷基 四氢吡喃-4-基; 苯乙基 被一个或多个卤素取代的苯乙基; 苯氧基甲基; 被一个或多个卤素取代的苯氧基甲基; 苄氧基乙基 由一个或多个卤素取代的苄氧基 - 乙基; 或为-NR2R3; R2是氢或低级烷基; R3为低级烷基; 四氢吡喃-4-基; -CH 2 - 环烷基 或任选被被一个或多个卤素取代的低级烷基取代的环烷基; 或者R 2和R 3与它们所连接的N-原子一起形成具有4或5个碳原子的杂环烷基,其任选被一个或多个选自卤素的取代基取代; 或被一个或多个卤素取代的低级烷基; X是-CH 2 - 或 - (CH 2)2 - ; Ar是苯基或吡啶基; R4是卤素; 低级烷基 被一个或多个卤素取代的低级烷基; 或低级烷氧基; n为1或2; 或其药物活性盐与立体异构体形式,包括式(IA)化合物的单独非对映异构体或对映异构体以及其外消旋或非外消旋混合物。 本发明还涉及式(IA)化合物用于治疗以细胞毒性TAU错误折叠和/或聚集为特征的某些神经变性疾病的用途。

    Methyl-pyrrolidine ether derivatives
    10.
    发明授权
    Methyl-pyrrolidine ether derivatives 有权
    甲基吡咯烷醚衍生物

    公开(公告)号:US08507535B2

    公开(公告)日:2013-08-13

    申请号:US13171507

    申请日:2011-06-29

    IPC分类号: A61K31/4439 C07D401/14

    摘要: The invention relates to a compound of formula wherein A is defined herein or to pharmaceutically active salts, stereoisomeric forms, including individual diastereoisomers and enantiomers of the compound of formula I as well as racemic and non-racemic mixtures thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

    摘要翻译: 本发明涉及下式的化合物或其药学上可接受的盐或其盐,其中A定义为本文或其药学活性盐,立体异构体形式,包括式I化合物的单独非对映异构体和对映异构体以及其外消旋和非外消旋混合物。 本发明化合物是用于治疗抑郁症,疼痛,精神病,帕金森病,精神分裂症,焦虑和注意缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。